Bayer. The merger with Schering has given a welcome boost to Bayer's pharmaceutical portfolio from new product launches at a time when the major players are facing holes in their drug pipelines. At the same time profitability is rising as cost savings are reaped. The company also benefits from a reasonably good crop science business, which until recently has been ignored by analysts and which should see a big pick-up in earnings as a result of the improving outlook for farmers.
| Sedol |
Type |
Price |
Date |
| 5069211 |
Buy |
EUR 58.781 |
23/10/2007 | |
